Cipla’s Managing Director and Global CEO Umang Vohra said the company delivered its highest-ever quarterly revenue in Q2 FY26, supported by broad-based growth across key markets and strong execution.
“We delivered our highest-ever quarterly revenue of ₹7,589 crore, with a robust EBITDA margin of 25%,” Vohra said, noting performance strength across India, US, Africa, and emerging markets.
Vohra underlined a 7% YoY growth in the India business and called the launch of Yurpeak (Tirzepatide) a “pivotal step into obesity care.” The US business posted $233 million in revenue, backed by differentiated assets, while emerging and European markets grew 15% YoY in USD terms.
He also indicated minor contribution from gRevlimid in Q3, but remained confident about base-business momentum and upcoming launches, subject to USFDA approvals.
Looking ahead, Vohra said Cipla will focus on expanding flagship brands, strengthening its product pipeline and addressing regulatory priorities.
